Stock listing
APLM Stock Price, News, Filings & Events — Apollomics Inc.
Selected listing: APLM · NASDAQ · USD · US
This page tracks Apollomics Inc.'s APLM:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following APLM:NASDAQ. APLM:NASDAQ is the stock-level entry point for investors researching Apollomics Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Apollomics Inc. is a public company traded under the ticker APLM in the American market. The company has a market capitalization of approximately $39.99 million. Apollomics focuses on developing innovative therapies to address unmet medical needs.
- Ticker
- APLM:NASDAQ
- Asset type
- Stock
- Market cap
- $67.6M
- Sector
- Finance
- Industry
- Financial Conglomerates
- Exchange
- NASDAQ
- Currency
- USD
Apollomics Inc. APLM:NASDAQ stock context
This page tracks Apollomics Inc.'s APLM:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following APLM:NASDAQ. APLM:NASDAQ is the stock-level entry point for investors researching Apollomics Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Apollomics Inc. is a public company traded under the ticker APLM in the American market. The company has a market capitalization of approximately $39.99 million. Apollomics focuses on developing innovative therapies to address unmet medical needs.
Latest news from Apollomics Inc.
Apollomics Announces $10 Million Private Placement Transaction
August 11, 2026
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
July 13, 2026
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
June 24, 2026
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
April 27, 2026
Apollomics Inc. Announces $2.0 Million Bridge Financing
April 1, 2026
Apollomics Inc. earnings calls
Research Apollomics Inc.
Apollomics Inc. investor report
Review AI stock analysis and investor report context for APLM:NASDAQ.
Apollomics Inc. company profile
View the public company page for Apollomics Inc. on 6ix.
Apollomics Inc. news
Read company news and market updates connected to Apollomics Inc..
Apollomics Inc. investor events
Find investor webinars, events, and replay context for Apollomics Inc..